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Adaptive immunity is essential for the survival of many different organisms. Immune 
system mechanisms differ between species, but they all have two things in common; 
adaptability and memory of the immune response. These depend on regulated and 
often irreversible alterations to the host genome. DNA damage signalling and repair is 
therefore closely linked with adaptive immunity. In this thesis, I will present the first 
part of two projects dealing with adaptive immunity of bacterial and mammalian 
organisms.  
I will explore the novel repair factor BRD8 and its potential role in both the DNA 
damage response pathway and in antibody diversification of mammals. BRD8 was 
implicated in CSR in a genome-wide short hairpin RNA screen. Preliminary data 
further implicates BRD8 in both DNA damage repair and antibody diversification. 
Murine BRD8 is highly expressed in immune cells, specifically immune cells 
undergoing antibody diversification. Both human and mouse BRD8 share homology 
with and interact with various known DNA damage repair proteins. Further studies will 
help reveal its exact role in both DNA damage repair and antibody diversification.  
I will also use the bacterial adaptive immune system, Clustered regularly-
interspaced short palindromic repeats (CRISPR)-Cas9 for gene editing. Modifications 
to the system has great potential for therapeutic and experimental uses. A model 
system based on 293T/GFP-puro cells was developed for rapid characterization of 
various Cas9 fusion variants we designed.  
RNA-deaminase Adar1 has been implicated in somatic hypermutation (SHM) [1], 
which in antibody diversification increases the affinity of an antibody for a specific 
antigen through mutations of the variable domain. I therefore fused the deaminase 
domain of Adar1 to the nuclease-deficient dCas9 in an effort to mimic somatic 
hypermutation ex vivo. The effects of Cas9 was assayed on the DNA level using a 
celery juice extract we have also developed and established. Preliminary data did not 
reveal any Adar1 deaminase activity on the eGFP locus, but ongoing studies seem 
more promising. A functional Adar1-dCas9 can potentially be used for in vivo single-
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Different immune system mechanisms can be found in different types of organisms, in 
agreement with their differences and the different types of pathogens they may expect 
to encounter. In bacteria, the CRISPR system specializes in the RNA mediated DNA 
cleavage of invading bacteriophage genomes. In vertebrates the system is much more 
complex, consisting of several specialized cell types. While the two systems differ in 
both their components and mechanisms, they share two common traits that are 
essential for their efficiency and speed; adaptability and memory. The ability of these 
organisms to store the recognition potential for pathogens and, upon subsequent 
encounters, utilise this to swiftly react to and dispose of the threat is the essence of 
the so-called adaptive immune response.  
The CRISPR-Cas9 system is a relatively new discovery, but it has already been 
harnessed as a powerful tool for genomic engineering. The vertebrate immune 
system, on the other hand, has been studied for more than a century, yet it has proven 
more elusive in terms of the underlying molecular mechanisms. As of yet, the ex vivo 
mimicry of adaptive immunity has been far less successful than CRISPR. The 
adaptability of immune systems is a complex topic, which can be approached from 
several angles. This thesis will tackle two of these angles, with particular emphasis on 
the overarching themes of adaptive immunity, and its tight association with the DNA 
damage response. In the first part of the thesis, I will explore a novel repair factor and 
its potential role in regulating the production and diversification of vertebrate antibodies 
in vivo. In the second part, I will seek to reduce the same process to its bare essentials 
and utilise the bacterial immune system CRISPR-Cas9 to mimic it ex vivo.  
 
5.1 CRISPR-Cas9 
The CRISPR-Cas immune systems, which are found in both bacteria and archaea [2], 
differ slightly from organism to organism. Common among them all are the two core 
components: the Cas protein capable of cutting DNA, and CRISPR targeting RNA 
(crRNA) that leads it to specific parts of the foreign DNA.  
As CRISPR depends on RNA-based targeting, it is highly specific and easily 





systems, such as zinc-finger nucleases (ZFNs) and transcription-activator-like effector 
nucleases (TALENs).  
While some CRISPR-Cas system types require multiple Cas proteins, Type II 
requires only one; Cas9. For simplicity’s sake, the CRISPR genomic engineering tool 
is therefore based on this system.  
 
5.1.1 The Type II CRISPR-Cas9 system relies on dual RNA-based targeting 
RNA-based targeting of foreign DNA is found in most bacteria and archaea[3]. The 
specificity of the system relies on the integration of genetic elements from the invading 
pathogen into a specific region of the bacterial genome. The integrated foreign DNA, 
so-called protospacers, are interspaced by short palindromic repeats. The whole 
region is known as the clustered regularly interspaced short palindromic repeats 
(CRISPR) and has thus given the CRISPR-Cas9 system its name [3].  
RNA, transcribed from these DNA regions, is processed and becomes the 
crRNA that guides the Cas9 protein specifically to the same invading bacteriophage 
genome if encountered a second time. A transactivating crRNA (tracrRNA) mediates 
the binding between the crRNA and Cas9. Cas9 cleaves the DNA at the protospacer 
adjacent motif (PAM). Importantly, the PAM is not contained within the protospacer or 
Figure 1: The CRISPR/Cas Type II system[140]. 
A. The CRISPR region is transcribed into pre-crRNA 
B and C. The tracrRNA mediates pre-crRNA processing and Cas9 binding.  





crRNA sequence, thus preventing the cleavage of the host CRISPR locus [4,5]. The 
PAM recognised by Cas9 differs between species [4,6,7].  
 
5.1.2 The CRISPR-Cas9 system can be hijacked and used for genome engineering 
The Type II CRISPR-Cas9 system forms the basis of the genome engineering 
CRISPR tools. It consists of two components; the Cas9 nuclease and a guide RNA 
(gRNA). The gRNA is a synthetically designed RNA sequence that combines the 
functions of the crRNA and tracrRNA [8] (see section 5.1.1). Cas9 has been codon 
optimised for expression in several species, including humans. The Church and Zhang 
labs produce the most commonly used vectors for expressing Cas9 and gRNA in 
several organisms.  
 Designing suitable gRNAs for a given target sequence has one main criterion: 
the presence of the PAM sequence immediately downstream of the gRNA 
complementary sequence. Cas9 from Streptococcus pyogenes (SpCas9) is the most 
commonly used Cas9. The PAM sequence recognised by the SpCas9 is NGG [9], 
making gRNA design possible for almost any region of a given genome in most 
organisms. Several bioinformatics tools have been developed for gRNA design. These 
consider potential off target sites, and ease the choice of the best suited gRNA for a 
given target [10] (http://www.addgene.org/crispr/reference/#grna).   
 The original CRISPR-Cas9 system was used for creating knock-outs. The DSB 
created by the Cas9 is generally repaired through the non-homologous end joining 
(NHEJ) pathway, which often results in a deletion or insertion [8]. Statistically, two 
thirds of the time (66%) this process causes a frameshift, and thus a knockout of the 
gene.  
 Cas9 binding to DNA through interaction with gRNA, and its ability to cleave 
DNA, are two independent functions. A dCas9 mutant unable to cleave DNA can 
therefore still be targeted to a specific region via gRNA. This allows for a multitude of 
modified CRISPR-Cas9 systems to be created, expanding the possible applications 
beyond gene knock-outs. Several proteins have been fused to dCas9, including other 






5.2 The vertebrate immune system 
Unlike bacteria, vertebrate pathogenicity relies mostly on protein, lipids, and sugar 
moieties. That is why the adaptive immune system of jawed vertebrates relies on 
antibodies, or immunoglobulins (Ig), for the recognition of invading antigens [15]. 
Mutations and recombination of the DNA at the Ig locus allows the immune system to 
produce a vast repertoire of antibodies from a single locus. This intentional DNA 
damage takes place in two developmental stages of B cells and, unsurprisingly, is 
tightly regulated [16,17]. Without these constraints, an organism would suffer from 
immune deficiencies and be susceptible to pathogen invasion, while increased or 
uncontrolled DNA damage can cause accumulation of mutations elsewhere in the 
genome and lead to cancerous growth [18].   
 
5.2.1 Antibody diversification  
The primary antibody diversification process of V(D)J recombination occurs in the 
bone marrow. It involves the rearrangement of the variable (V), joining (J) and diverse 
(D) segments to make up the variable region of the Ig gene. At this stage, the B cells 
are capable of producing a wide array of antibodies. However, their affinity for antigens 
remains limited and, as they maintain expression of the same precursory effector 
region, their potential effector functions are restrained. Effector functions determine 
the mechanism of pathogen elimination, as well as antibody localisation [19]. 
 Upon antigen engagement, B cells enter germinal centres in lymphatic tissue 
where secondary antibody diversification takes place. Somatic hypermutation (SHM) 
of the variable region increases the affinity of the antibody for specific antigens, while 
class-switch recombination (CSR) exchanges the IgM constant region with other 
constant regions such as IgG and IgA. Both of these processes are initiated by the 
small mutator protein activation-induced cytidine deaminase (AID). AID deaminates 
cytosines resulting in U:G mismatches in the DNA sequence.  
 For SHM, AID mutations initiate the accumulation of point mutations in the 
variable region, altering the tertiary structure of the antibody and thus allowing 
increased affinity for encountered antigens. In CSR, AID exerts its activity at switch 
regions upstream of the different constant regions. Here the AID-initiated damage 






5.2.2 SHM involves mutations at both G-C and A-T base pairs 
During SHM the mutation rate at the variable region of the Ig locus increases to 10 -3 
mutations per base pair per generation. This is 106 times higher than the background 
mutation rates in the cells [20,21]. All four bases are mutated, with C:G and A:T pairs 
being targeted approximately equally [21,22]. All mutations depend on the activity of 
AID [23], but only the C:G pairs are directly altered by AID. The mutations affecting 
A:T pairs are dependent on the mismatch repair system; in particular Msh2 and Msh6 
[24–26]. The Msh2-Msh6 heterodimer has been proposed to recognise the AID-
generated U:G mismatches and recruit low-fidelity polymerases which amplify the 
mismatches in the variable region [26,27].  
 
5.2.2.1 AID initiates SHM by deaminating cytosines  
AID deaminates cytosine residues to create U:G mismatches. It has been shown that 
in vitro AID acts only on ssDNA, and not RNA, dsDNA or DNA/RNA hybrids [28]. It 
preferentially targets RGYW/WRCY (R = A/G, W=A/T and Y=C/T) hotspot motifs [22]. 
C and G mutations occur at a similar frequency, indicating that AID targets both the 
transcribed strand (TS) and non-transcribed strand equally [29].  
The U:G lesions can result in a mutated DNA sequence by way of different 
mechanisms through either replication or erroneous repair.  First, as dU is read as dT 
by the replication machinery, one daughter cell would acquire a G-to-A mutation during 
replication during cell division (should the U:G mismatch go unnoticed). Second, if the 
dU is excised, error-prone base excision repair can then potentially fill the gap with 
any base. Third, the aforementioned mismatch repair can recognise the mismatch and 
through non-canonical pathways recruit error-prone polymerases; opening the 
sequence up for a myriad of mutations at both C:G and A:T pairs [21]. One such error-
prone polymerase is polymerase eta (Pol η). 
 
5.2.2.2 Adenine mutations cannot be explained solely by DNA polymerase η activity  
Pol η has been shown to be important for the A:T mutations of SHM [30]. Pol η is a 





bypass UV-induced damage by accurately replicating DNA with thymine-dimers. 
However, its fidelity when replicating non-damaged bases is low, with base-
substitutions occurring at a rate of 10-2 to 10-3 [31,32]. Patients with xeroderma 
pigmentosum have mutations in Pol η and are sensitive to sunlight. Sequencing data 
from such patients reveal that in the absence of Pol η, the Ig variable regions have a 
decrease in A:T mutations without affecting the overall mutation rate [33,34]. Similar 
patterns have been observed in mice deficient in Pol η [35–37]. Furthermore, Pol η 
has been shown to have a preference for WA motifs when mis-incorporating bases; 
WA being the A:T hotspot in somatic hypermutation [38]. 
 While this all appears to be fairly conclusive, issues have been raised with this 
interpretation of the Ig variable region sequencing data [39,40]. The main focus of 
these critiques is that while C and G mutations caused by AID occur with a similar 
frequency on both strands, the A and T mutations exhibit a strand bias with a 2-fold 
increase in mutations of A relative to T on the non-transcribed strand [41]. Although 
reports have shown that Pol η contributes to this strand bias [42], a plausible 
mechanism behind this bias has yet to be illustrated [39,40]. Why would Pol η be 
recruited to the non-transcribed strand more than the transcribed strand, when AID 
targets both equally? The mechanism is not known, but AID expression levels [29] and 
the UNG and Msh2/Msh6 pathways [43] are contributing factors. It appears that there 
is still a long way to go before we resolve the full mechanism behind somatic 
hypermutation. It certainly opens up the possibility of additional factors contributing to 
the generation of the A:T mutations.  
 
5.2.2.3 The reverse transcriptase model of SHM 
One theory, put forward by Edward J. Steele, involves an RNA intermediate. It is 
argued that SHM stems from both DNA and RNA mutations which are coupled by a 
reverse transcriptase [39]. Edward J. Steele and colleagues have shown that Pol η 
itself can function as a reverse transcriptase in vitro [30]. This theory allows the 
possibility of the involvement of RNA editing proteins in SHM, including the Adenosine 






Steele proposes that Adar1 deaminates adenosines in dsRNA stem loops of 
nascent mRNA [39] based on a statistical correlation between the frequency of WA-
to-WG mutations and the number of predicted mRNA hairpins for the site [45]. Pol η 
would then reverse transcribe the mutated mRNA into cDNA, which would serve as a 
template for replicating the non-transcribed strand [39] (see Fig.2).  
 
5.2.2.4 Adar1 deaminates adenosines near mismatches  
Steele’s reverse transcriptase model for SHM is interesting and strongly supported by 
robust statistical data. However, there is very little supporting experimental evidence 
for this complex theory. Therefore, a different scenario should also be considered: the 
possibility that Adar1 also exerts its adenosine deaminating activity on DNA. Indeed, 
two isoforms of Adar1 exist; the constitutively expressed shorter isoform, and the 
interferon-inducible longer isoform which contains an N-terminal Z-DNA binding 
domain [46–48]. The biological role of this Z-DNA binding domain has yet to be 
clarified, but it has been proposed that it directs Adar1 to highly transcribed genes [49]. 
Z-DNA is a left-handed double helix [50]. Negative supercoiling, which appears 
upstream of an active RNA polymerase, has a stabilizing effect on Z-DNA [51,52].  
Figure 2: Edward J. Steele’s ‘Reverse 
transcriptase model of SHM[39]: 
transcription-coupled DNA and RNA 





 Recently, a correlation between overexpression of Adar1 and an accumulation 
of somatic DNA mutations in Bcl6-deficient cells was shown [1]. Bcl6 is a 
transcriptional repressor [53], which inhibits cell senescence [54]. It has also been 
implicated in antibody diversification; Bcl6 knockout mice have impaired germinal 
centre B cell formation [55–57]. Sequencing of the Ig-Sµ region in Bcl6 deficient IgG1 
cells revealed an increase in somatic mutations. The majority of the mutations were 
A:T mutations. Adar1 was found to be overexpressed in the Bcl6 deficient cells. 
Furthermore, exogenous overexpression of Adar1 can induce accumulation of somatic 
hypermutation without AID expression [1].  
Figure 3: Schematic illustration of chromatin modifications at the Ig locus during secondary antibody 
diversification*.  
A. The Ig locus and the histone modifications that contribute to the regulation of SHM and CSR. Green 
modifications are associated with Ig locus transcription. Blue modifications are integral to AID targeting and 
generation of DSBs in CSR. Orange modifications are involved in signalling and protein recruitment during the 
repair phase subsequent to AID-induced DNA damage.  
B and C. The Eµ enhancer associates with the 3’ regulatory region (3’RR), bringing switch regions into close 
proximity.  
D. Class-switch recombination occurs when the DSBs are repaired in such a way that the DNA segment between 
the two switch regions is lost.  
E. The Ig locus after CSR; now expressing the IgA antibody.  





 One quality of Adar1 that is especially interesting, when seen in the light of a 
possible role in SHM, is its preference for deaminating adenosines near mismatches. 
The secondary structure of the targeted dsRNA has been shown to determine the 
specificity and efficiency of Adar1 adenosine deamination [58,59]. The specificity or 
efficiency of Adar1 deamination is not dependent on its dsRNA binding domains[58]. 
The efficiency of deamination is decreased in Adar1 constructs with mutated Z-DNA 
binding domains, but only when editing minimal substrates; 15 bp dsRNA stem [58]. 
Which adenosine within a sequence Adar1 targets is dependent on mismatches within 
the region. A mismatched adenosine is preferentially edited by Adar1[58]. Editing can 
also occur in the absence of this mismatch, but for those substrates a G:U mismatch 
occurred nearby [58]. Recently, it has been shown that the requirement for a mismatch 
at the targeted adenosine is dependent on the surrounding bases with the 5’ neighbour 
having the biggest influence. The data also support the notion that a mismatch at a 
nearby C:G pair increases specificity and efficiency in the absence of a mismatch at 
the targeted adenosine [59].  
 I postulate that, if Adar1 is indeed capable of deaminating deoxy-adenosines, 
the mismatches induced by AID may serve as a substrate recruitment platform. 
Furthermore, as the Ig locus is highly transcribed [60], Z-DNA formation is likely and 
could also help recruit Adar1 to the region. More studies are needed in order to 
elucidate the possible role of Adar1 in somatic hypermutation.  
 
5.2.3 Successful CSR depends on chromatin modifications  
Both SHM and CSR are orchestrated by chromatin modifications. Recruitment of AID, 
and the repair of AID induced DNA damage, are in large part regulated by signalling 
cascades involving histone modifications; including ubiquitination, phosphorylation, 
methylation and acetylation (see Fig.3). The following introductory chapters will focus 
on the chromatin modifications that are essential for successful CSR to occur. It is 
worth noting that additional regulatory and signalling elements are involved, including 






5.2.3.1 Donor and recipient switch regions are marked by histone modifications prior 
to DSBs 
Specific stimuli drive CSR in B cells towards a particular Ig isotype. The exact 
mechanism with which the donor and the desired recipient switch region are 
selectively targeted, has not been fully elucidated, but specific histone modifications 
have been implicated as markers for these regions prior to DSB initiation (see Fig.3A). 
It seems plausible that these histone marks could function as recruitment platforms for 
AID or other components of the CSR machinery.  
 H3K4me3 has been implicated as a marker for IgA switching in CH12F3-2A cell 
lines[62,63]. It is facilitated by the FACT complex, a potent chromatin modifying 
complex. Knockdown of the FACT components SSRP1 and SPT16 caused a general 
decrease in H3 methylation in the Sµ region and a specific reduction of the H3K4me3 
mark in the Sα region, correlating with a significant decrease in IgA switching[63]. The 
reduction in H3K4me3 led to an decrease in DNA breaks at the switch regions, 
however the intermediate steps between histone mark and DSB creation remain to be 
elucidated [62,63]. Knockdown of the histone chaperone Spt6 also leads to a decrease 
in the H3K4me3 mark in Sµ and Sα, along with a subsequent reduction in DSBs in the 
two regions[64]. This further supports the role of H3K4me3 in CSR and implicates Spt6 
as a regulator of the mark. Interestingly, the Spt6 knockdown also led to a decrease 
in H3K4me3 in the variable region, losing SHM [65], while previous reports did not see 
any effect in the variable region [66].   
 The histone modifications H3K9me3 and H3K9ac are also found at S regions 
involved in recombination[67]. They depend on cytokine stimulation but not AID 
expression. Therefore, they are thought to proceed, or maybe even be directly 
involved in, AID recruitment to the switch regions and subsequent recombination [67]. 
Outside the Ig locus the H3K9me3 mark has been shown to play a role in DSB repair 
rather the generation of DSBs. It functions through a direct interaction with the histone 
acetyltransferase Kat5, and abrogation of the H3K9me3 mark causes defective DSB 
repair [68,69] (see section 5.2.3.3). This implies that H3K9me3 may have a role in 
both targeting and repair of DSBs in CSR.  
A fourth combinatorial histone mark of H3K9ac and H3S10ph, has also been 





region was found to be enriched in H3K9acS10ph. Upon cytokine activation, the 
desired recipient S region also became enriched in the mark [70]. A direct interaction 
between H3S10ph and the 14-3-3 adapters has been determined. The addition of an 
acetyl group to K9 of the same histone increases the affinity of this interaction [71,72]. 
This is particularly interesting because the 14-3-3 complex binds AID and 5’-AGCT-3’ 
motifs that are found in both switch regions and the variable region. Furthermore, 
upregulation of 14-3-3 correlates with increased CSR [73]. Altogether this hints at a 
role for H3K9ac/H3S10ph as a recruiter of 14-3-3 to mediate the recruitment of AID to 
the switch regions.  
 
5.2.3.2 Histone modifications recruit DSB repair proteins in CSR 
Post AID-induced DSB creation, two things are important. First, the DSBs must be 
repaired to maintain genome stability. Second, the DSBs must be repaired in such a 
way that the donor and desired recipient switch regions are recombined and the 
intervening DNA is lost (see Fig.3D). The repair proteins needed for this process are 
recruited through a signalling cascade that includes multiple histone modifications. 
One protein that has a well-established role in DSB repair, including CSR-dependent 
DSBs, is 53BP1 [74–80]. Various pathways involving chromatin modifications are 
involved in the recruitment of 53BP1 to DSB sites.  
 The histone mark H4K20me2 recruits 53BP1 through a direct interaction with 
the Tudor domain of 53BP1 [81,82]. Lack of H4K20me2 enrichment at DSBs, caused 
by the loss of the methyltransferase MMSET, has been shown to result in poor CSR 
[83]. 
 Some of the earliest measured histone modifications to appear at DSBs are 
phosphorylated H2AX (γH2AX) and H4ac. The kinase ATM is responsible for 
phosphorylating H2AX in DSBs. In typical DNA repair, it has been shown that the 
activation of ATM prior to H2AX phosphorylation is dependent on the aforementioned 
Kat5. Upon binding to H3K9me3 (see section 5.2.3.1), through its chromodomain, 
Kat5 recruits and acetylates ATM, which in turn autophosphorylates [84]. 53BP1 binds 
γH2AX through its BRCT domain and aides DSB repair by bridging the broken ends 





 The BET family member Brd4 interacts with acetylated histones through its two 
bromodomains [86] and has been found to play a role in DSB repair during CSR [87]. 
Indeed, knockdown or inhibition of Brd4 resulted in a decrease in CSR in CH12F3-2A 
cells (REF). It also reduced 53BP1 and UNG (another DNA repair protein) occupancy 
at switch regions. Importantly it did both without affecting the H4 acetylation. 
Chromatin Immunoprecipitation (ChIP) and immunoprecipitation assays confirmed an 
interaction between Brd4 and 53BP1, H4ac and γH2AX. On this basis, Brd4 has been 
proposed to function as a chromatin-bound platform for 53BP1 and UNG [87].  
 Finally, a ubiquitination pathway has also been implicated in the recruitment of 
53BP1 to DSBs [88]. It involves two E3 ubiquitin ligases; RNF8 and RNF168. RNF8 is 
initially recruited to DSBs by the ATM mediated phosphorylation of MDC1 (mediator 
of DNA damage checkpoint 1) at a TQxF consensus site. Upon recruitment, RNF8 
ubiquitinates H2A histones at the DSB site. This in turn recruits RNF168 which 
amplifies the ubiquitin signal through polyubiquitination. Knockdown of either RNF8 or 
RNF168 causes reduction in the accumulation of 53BP1 at AID-induced DSBs as 
measured by immunofluorescence in CH12F3-2A cells[88]. A concomitant reduction 
in CSR was also measured [88]. In recent studies, RNF168 has been shown to 
monoubiquitinate H2A on lysine 13 and 15 [89,90]. In accordance with this, 53BP1 
has been shown to bind H2AK15ub directly through an ubiquitination-dependent 
recruitment motif [82]. So it seems the ubiquitin mark itself mediates the recruitment 
of 53BP1. Indeed, the reduced accumulation of 53BP1 at DSBs in RNF8 and RNF168 
deficient cells can be rescued with the expression of an ubiquitin-H2AX fusion protein 
[91].  
It is apparent that a myriad of proteins are involved in CSR. However, there are 
still large gaps in our understanding of the “epigenetic” mechanisms that target AID to 
regulate efficient CSR and antibody diversification in general. This opens up the 
possibility of novel proteins serving important roles. A genome-wide short hairpin RNA 
screen our lab has previously conducted has implicated, among other hits, the 
bromodomain protein BRD8 in CSR and possibly other DNA damage response 






5.2.3.3 BRD8 is a chromatin reader 
Relatively little is known about BRD8 protein. From its sequence we can infer that it 
contains one, possibly two, bromodomains (see section 7.2.1 and 7.2.2) which are 
known to bind acetylated protein moieties [92]. This is particularly exciting in light of 
the multitude of chromatin modifications (including acetylations) that are essential for 
CSR. As mentioned previously, the related protein Brd4 has been shown to have a 
role in CSR (see section 5.2.3.2). Furthermore, it has been reported that human 
bromodomain-containing proteins play an essential role in the DNA damage response 
[93].  
 Overexpression of BRD8 has been implicated as an important factor in 
colorectal cancer[94]. Indeed, it was linked to the increased resistance to 
chemotherapy of these cancers[94]. The resistance is caused by reduced spindle 
poison sensitivity. Spindle poisons activate the spindle checkpoint, initiating mitotic 
arrest followed by cell death or senescence. BRD8 siRNA mediated knockdown in 
various cell lines showed increased sensitivity to spindle poisons [94]. This further 
implicates BRD8 in the DNA damage response and associates it with adequate 
maintenance of genomic stability.  
BRD8 is sometimes known as TRCp120, because it was originally identified as 
a nuclear receptor coactivator of the thyroid hormone receptor [95]. Its potential role 
in transcription activation has later been supported by immunoprecipitation assays 
revealing that BRD8 is a subunit in the NuA4 HAT complex [96,97], which functions in 
transcriptional activation [98]. More importantly, when considering a possible role for 
BRD8 in CSR; the NuA4 HAT complex, of which BRD8 is a member, also has a role 
in DSB repair [98]. In fact, the previously mentioned Kat5, also known as Tip60, is the 







5.3 Aims and objectives 
5.3.1 Developing a modified CRISPR-Cas9 system 
The CRISPR-Cas9 genome engineering system has been modified before in various 
ways. Fusing the inactive dCas9 to other proteins allows us to utilise the readily 
adaptable RNA-directed targeting and combine it with the catalytic activity of another 
protein. In this project, I will construct an Adar1-dCas9 fusion protein to allow specific 
targeting of Adar1 dependent point mutations. To do this, I must:  
1. Design and construct an Adar1-dCas9 fusion expression system 
2. Design suitable gRNAs for targeting wildtype Cas9 and Adar-Cas9 to eGFP 
3. Assay the effects of Cas9 variants using celery juice extract assay and flow 
cytometry 
 
5.3.2 Assessing the role of BRD8 in antibody diversification and DNA damage repair 
BRD8 has been implicated as a possible important factor in both the DNA damage 
response and antibody diversification. In this project I will begin to unravel the role of 
BRD8 in these interconnected processes. I will:  
1. Assess the likelihood of a role for BRD8 in the DNA damage response and in 
antibody diversification using available data 
2. Transfect 3T3 cells with BRD8 gRNAs 





6 Methods and Materials 
6.1 Developing a modified CRISPR-Cas9 system 
6.1.1 Constructing Adar-Cas9 expression plasmid 
The human codon-optimized Streptococcus pyogenes Cas9 nuclease with mutations 
D10A and H840A (Addgene #47314 [99]) was used as expression vector. The plasmid 
is hereby referred to as the dCas9 plasmid.  
Primers were designed to amplify the Adar1 deaminase domain from FLIS-
Adar1 plasmid, kindly provided by Joana M. P. Desterro, while adding a SpeI 
restriction site, a FLAG-tag and a XTEN-linker at the C-terminus of the deaminase 
domain. In addition, a XbaI restriction site was included at the N-terminus. The final 









 Both the dCAs9 plasmid and the FLIS-Adar1 plasmid contains an ampicillin 
resistance gene. The Adar insert was therefore amplified through two consecutive 
PCRs in order to avoid contamination with the FLIS-Adar1 plasmid in the ligation 
colonies. The first PCR was performed with RedTaq® ReadyMix™ PCR Reaction Mix 
(R2523, Sigma Aldrich) in 25µl with 100µM of each primer, 1 ng plasmid DNA and a 
program of: 94˚C x 5min, 20 cycles of (94˚C x 30s, 55˚C x 30s, 72˚C x 1min10s), 72˚C 
x 5min. The second PCR was performed in a similar 25µl reaction with 1 µl of a 1/500 
dilution of PCR#1 as DNA template and a program of: 94˚C x 5min, 30 cycles of (94˚C 





 The Adar insert was digested with FastDigest restrictions enzymes SpeI (BcuI) 
and XbaI, and the m2 plasmid with FastDigest restriction enzyme XbaI (FD0684, 
Thermo Scientific), for 7min at 37˚C in FastDigest buffer. 330 ng Adar insert was 
ligated into 90 ng linearized m2 plasmid in a 10 µl volume using Rapid DNA Ligation 
Kit (K1422, Thermo Scientific). The ligation mix was left at room temperature for 10 
min.  The ligated plasmid was transformed into NEB 5-alpha Competent E.coli; 5-10µl 
DNA added to 50µl competent cells, then incubated on ice for 30 min, heat shocked 
at 42˚C for 45s, on ice for 5 min and left to recover in LB at 37˚C, and plated on LB, 
100µg/ml ampicillin plates. Plates were left at 37˚C overnight.  
 The following day colonies were picked, dipped in PCR mixture for colony PCR 
and used to inoculate overnight cultures in 5ml LB, 100µg/ml ampicillin media. Colony 
PCR was performed with RedTaq® ReadyMix™ PCR Reaction Mix (R2523, Sigma 
Aldrich) in 12.5µl with 2µM of each primer and a program of: 94˚C x 5min, 30 cycles 
of (94˚C x 30s, 55˚C x 30s, 72˚C x 1min10s), 72˚C x 5min. The primers used were 
RCOL252 (5’-CGCAAATGGGCGGTAGGCGTG-3’) and RCOL254 (5’-
TGGAGTACTTCTTGTCCATGGTGGCA-3’). They are situated in the plasmid 
sequence on either side of the XbaI restriction site (see Fig.4).  
Overnight cultures testing positive for the insert were spun down and plasmid 
was purified from the cell pellets using GeneJET Plasmid Miniprep Kit (K0502, Thermo 
Scientific). Concentrations of plasmid DNA was measured by Nanodrop. The 
orientation of the insert in the plasmids was confirmed by subsequent PCR reactions 
performed using RedTaq® ReadyMix™ PCR Reaction Mix (R2523, Sigma Aldrich) in 
25µl with a program of: 94˚C x 5min, 30 cycles of (94˚C x 30s, 55˚C x 30s, 72˚C x 
1min10s), 72˚C x 5min, 10ng of plasmid and 2µM of each primer for the primer 
combinations RCOL252/RCOL290 and RCOL252/RCOL289 (see Fig.4). Positive 
Figure 4: Genetic map for the ligation of Adar1 deaminase insert into m2 plasmid.  





results were verified by sequencing (Eurofins) using RCOL252 and RCOL321 (5’-
CGATCGGTATTGCCCAGAAC-3’).  
 
6.1.2 EGFP gRNA design and plasmid construction 
In order to test the activity of the Adar-Cas9 fusion protein compared with other Cas9 
variants, gRNAs targeting eGFP of the 293T/GFP-puro cell line (AKR-202, 
2BScientific) were designed. Suitable gRNAs were chosen based on scores given by 
the gRNA prediction softwares CRISPRdirect [10] and Feng Zhang lab’s Target Finder 
(http://crispr.mit.edu/), as well as the expected activity of the Adar-Cas9 fusion protein.  
 The designed gRNAs were synthesized according to the Church hCRISPR 
gRNA synthesis protocol (https://www.addgene.org/crispr/church/) and ligated into the 
gRNA_Cloning Vector (Addgene #41824[100]).  
 
6.1.3 Transfection of 293T/GFP-puro cells 
All 293T/GFP-puro cell growth took place in DMEM media, 2µg/ml puro (DMEM-puro 
media) at 37˚C. Using polyethylenimine (PEI), cells were transfected with a 
combination of the constructed eGFP gRNA and Adar-Cas9 plasmids, the original 
FLIS-Adar1 plasmid, wtCas9 plasmid (Addgene #41815[101]), m2Cas9 plasmid 
(Addgene #47314[99]) and myc gRNA plasmid previously constructed by Laurence 
Higgins. Two dish/well sizes were used and the cell number and DNA concentrations 
were adjusted accordingly. Below are the methods for the 6-well plate. Cells 
transfected in 6cm dishes were incubated with triple the amount of DNA. In 
accordance with this, the amount of cells seeded was also tripled.   
For the 6-well plate ~100,000 293T/GFP-puro cells/well were seeded and 2 ml 
DMEM-puro media was added the day before transfection. The DNA mix was 
prepared in 250µl OPTIMEM/well in Eppendorf tubes. A total of 5µg of DNA, 2.5µg 
Cas9 variant plasmid and 2.5µg gRNA plasmid, was incubated with 15µl PEI (3µl PEI 
per 1µg DNA) at room temperature for 15 min. For control samples containing only 
Cas9 or gRNA plasmid the total DNA amount was 2.5µg and the PEI volume 7.5µl. 
Post incubation DNA mix was added to each well and the cells were left for 3 hours 






6.1.4 Celery Juice Extract Assay  
Analysis of the effects of Cas9 at the DNA level was based around a mismatch-specific 
nuclease. The assay consisted of four steps; 1. PCR and PCR purification, 2. 
Heteroduplex formation, 3. Digest with mismatch-specific nuclease and 4. 
Visualisation of the reaction on a gel. The mismatch-specific nuclease was extracted 
from celery.  
 
6.1.4.1 Preparation of celery juice extract 
The celery juice extraction was modified from a published protocol [102]. One bunch 
of celery was washed and blended with water. The blended celery was filtered and 
spun down for 20 min at 2600 g. The supernatant was transferred to a clean tube. 1 
M Tris and phenylmethanesulfonyl fluoride (PMSF) was added to the solution for a 
final concentration of 0.1 M Tris-HCl, pH 7.7, 100 µM PMSF.  
 144 g (NH4)2SO4 was added per litre of solution for a final solution of 25% 
(NH4)2SO4. The solution was mixed for at 4˚C for 30 min and spun down 20,000 g at 
4˚C for 30 min. The supernatant was transferred to a clean tube.  
 390 g (NH4)2SO4 was added per litre of solution for a final solution of 80% 
(NH4)2SO4. The solution was mixed for at 4˚C for 30 min and spun down 20,000 g at 
4˚C for 60 min. The supernatant was discarded. The pellet was resuspended in 0.1M 
Tris-HCl pH 7.7, 0.5M KCl, 100 µM PMSF followed by overnight dialysis in 10L of 
same buffer.  
 
6.1.4.2 eGFP primer design 
Primers were designed for the eGFP DNA sequence using Primer3 [103,104]. Primers 






6.1.4.3 Verifying the CJE assay with control DNA  
Two variants of control DNA with known mismatches between them were amplified 
from two plasmids and purified using the GeneJET PCR Purification Kit (K0701, 
Thermo Scientific) by Angelina Block.  
The purified DNA samples were normalized to a concentration of ~50ng/µl. Two 
20 µl samples in Phusion HF buffer (F-518L, Thermo Scientific) were prepared for 
heteroduplex formation; control DNA variant 1 alone and a 1:1 ratio of the two variants. 
To facilitate heteroduplex formation, DNA was denatured and reannealed in 
thermocycler under the following conditions: 95˚C x 10 min, 95-85˚C at -2˚C s-1, 85 ˚C 
x 1 min, 85-75˚C at -0.3˚C s-1, 75˚C x 1 min, 75-65˚C at -0.3˚C s-1, 65˚C x 1 min, 65-
55˚C at -0.3˚C s-1, 55˚C x 1 min, 55-45˚C at -0.3˚C s-1, 45˚C x 1 min, 45-35˚C at -0.3˚C 
s-1, 35˚C x 1 min, 35-25˚C at -0.3˚C s-1, 25˚C x 1 min, 25-10˚C at -0.3˚C s-1, 10˚C hold.  
 For the digest 4µl of CJE was added, and the solution was left to incubate for 
45 min at 45˚C. Afterwards, 2µl 0.25M EDTA was used to stop the reaction, and 
samples were run with loading dye on a 1% agarose TAE buffer gel at 110V for 30 
min. The gel was stained with Midori Green Advance (MG04, Geneflow) and visualized 
under UV. 
 
6.1.4.4 Analysis of the Cas9 effects on the GFP locus 
Genomic DNA was extracted using the GeneJET Genomic DNA Purification Kit 
(K0721, Thermo Scientific) from both the transfected cells and untransfected control 
cells. The DNA was eluted in 100µl 55˚C water. Using suitable primers (see section 
6.1.4.2) the region expected to contain the mismatch was amplified using PCR 
performed with RedTaq® ReadyMix™ PCR Reaction Mix (R2523, Sigma Aldrich) in 
50µl with 100-200ng genomic DNA, 2µM of each primer and a program of: 94˚C x 
5min, 30 cycles of (94˚C x 30s, 55˚C x 30s, 72˚C x 30s), 72˚C x 5min. The PCR 
products were purified using the GeneJET PCR Purification Kit (K0701, Thermo 
Scientific).  
 The purified DNA samples were normalized to a concentration of ~50ng/µl. 
Three 20 µl samples in Phusion HF buffer (F-518L, Thermo Scientific) were prepared 





two. The experimental DNA was then treated in the same manner as the control DNA 
(see section 6.1.4.3).  
 
6.1.5 Flow cytometry 
Cells were fixed in 1% PFA/PBS. Using a BD FACSCalibur the GFP signal of GFP 
negative 293A cells, and transfected and control 293T/GFP-puro cells was measured 
and analysed.  
 
6.2 Assessing the role of BRD8 in antibody diversification and DNA damage 
repair 
6.2.1 BRD8 sequence conservation and ancestry 
BRD8 protein sequences from different species were retrieved from NCBI Reference 
Sequence Protein database [105].  Sequences from Homo sapiens, Pan troglodytes, 
Mus musculus, Felis catus, Pteropus vampyrus, Chelonia mydas, Xenopus (Silurana) 
tropicalis, Danio rerio, Xiphophorus maculatus, Esox lucius, Stegodyphus 
mimosarum, Drosophila melanogaster and Ustilago maydis 521 were aligned in 
Jalview [106] using Muscle multiple alignment. The long isoforms were also aligned 
separately using the same conditions. Domains were predicted using the SMART 
software [107].  
 
6.2.2 Interaction networks of human and mouse BRD8 
The interaction networks of human and murine BRD8 were examined using the 
STRING database [108] of known and predicted protein interactions. The information 
is based on different lines of evidence originating from four different sources; genomic 
context, high-throughput experiments, conserved co-expression and previous 
knowledge. On the basis of these lines of evidence, each protein-protein interaction is 






6.2.3 Expression levels of BRD8 
Expression levels of BRD8 in different tissues and cell types was assessed based on 
RNA seq data from BioGPS [109] and microarray data from Immgen [110]. The 
BioGPS RNA seq raw data was processed and normalized using MEF values by Leo 
Bennett.  
 
6.2.4 Subcellular localization of BRD8 
Subcellular localization data for BRD8 in U-2OS cells was available from Protein Atlas 
[111].   
 
6.2.5 BRD8 gRNA design 
Two gRNAs for exon 2 of the BRD8 gene in M. musculus were designed by Leo 
Bennett and ligated into px260-U6-DR-BB-DR-Cbh-NLS-hSpCas9-NLS-H1-
shorttracr-PGK-puro vector (Addgene #42229[4]).  
 
6.2.6 3T3 cells transfection 
All 3T3 cell growth took place DMEM media at 37˚C. The day before transfection 
~100,000 3T3 cells/well were seeded in a 6-well plate and 2 ml DMEM media was 
added. On the day of transfection the DNA mix was prepared in 250µl OPTIMEM/well 
in eppendorf tubes. A total of 5µg of DNA was incubated with 15µl PEI (3µl PEI per 
1µg DNA) at room temperature for 15 min. Post incubation DNA mix was added to 
each well and the cells were left for 3 hours before the PEI was removed through a 
media change. Genomic DNA was extracted after 72 hours (see section 6.2.8).  
 
6.2.7 CH12 cells 
CH12 cells previously transfected with the BRD8 gRNAs and frozen by Leo Bennett 






6.2.8 Celery Juice Extract Assay 
Genomic DNA was extracted using the GeneJET Genomic DNA Purification Kit 
((K0721, Thermo Scientific) from both the transfected cells and untransfected CH12 
and 3T3 cells. The DNA was eluted in 100µl 55˚C water.  
 Using primers RCOL270 (5’-CTACTATCGTGTGACTGATCCTGG-3’) and 
RCOL271 (5’-CTTAAATTGGAGGGATGGCTGTAC-3’) a 668bp region around the 
gRNA targets was amplified using PCR performed with RedTaq® ReadyMix™ PCR 
Reaction Mix (R2523, Sigma Aldrich) in 50µl with 100-200ng genomic DNA, 2µM of 
each primer and a program of: 94˚C x 5min, 30 cycles of (94˚C x 30s, 55˚C x 30s, 
72˚C x 35s), 72˚C x 5min. The PCR products were purified using the GeneJET PCR 
Purification Kit (K0701, Thermo Scientific) with elution in 50µl 55˚C water.  
 The purified DNA samples were normalized to a concentration of ~50ng/µl. 
Three 20 µl samples in Phusion HF buffer (F-518L, Thermo Scientific) were prepared 
for heteroduplex formation; wild-type DNA, experimental DNA and a 1:1 ratio of the 
two. The experimental DNA was then treated in the same manner as the control DNA 
(see section 6.1.4.3). 
 
6.2.9 Visualising BRD8 localisation using BRD8 antibody 
293A human cells and 3T3 murine cells were seeded on 13mm objective glasses in 
24-well plates and grown in 0.5ml DMEM media per well. Prior to fixation cells were 
treated with 1µM camptothecin for 45 min.  
Cells were washed in PBS, permeabilized with 2%PFS in PBS for 15 min and 
blocked with 5% FCS, 0.05% TritonX in PBS. Cells were incubated overnight at 4˚C 
with Rabbit anti-BRD8 (A300-219A-T, BETHYL) at a 1:100 dilution as per 
manufacturer’s instruction and Ms mAb to γH2AX (ab26350, abcam) at a 1:500 
dilution, both in 5% FCS, 0.05% TritonX in PBS. After three washes with 0.05% TritonX 
in PBS, the cells were incubated at room temperature in the dark for 45 min with 
secondary antibody conjugates Goat pAb to Ms IgG, Alexa FluorTM 488 (ab150117, 








7.1 Developing a modified CRISPR-Cas9 system 
7.1.1 Constructing Adar-Cas9 expression plasmid 
The colony PCR revealed that colonies 7, 10, 13, 15, 18 and 19 had taken up plasmid 
containing the insert, while others had taken up re-ligated m2 plasmid (see Fig.5A). 
Multiple colonies appeared to 
contain several plasmid variants. 
The cause of this can most likely 
be found in either the 
transformation step or the picking 
of the colonies for the PCR. During 
the transformation single bacterial 
cells may have taken up more than 
one plasmid. When preparing the 
colony PCR, although care was 
taken, it is possible that two or 
more colonies were picked as one.  
Subsequent PCRs on the 
purified plasmid from the colonies 
containing the plasmid with the insert confirmed the orientation of the insert. Colony 7 
was the only unambiguous colony with the insert in the correct orientation. Sequencing 
confirmed the orientation of the insert. The two primers either end of the insert enabled 
the verification of the entire sequence of the insert and the two ligation sites. Colony 7 
was used for subsequent experiments.   
 
7.1.2 eGFP gRNA design 
For the design of suitable gRNAs for eGFP, several criteria had to be met; some of 
which were based on the expected activity of the Adar-Cas9 fusion protein.  
First, target options were considered taking two things into account; the 5’ 
(T>A>C>G) and 3’ (G>C=A>T) nearest neighbour preferences of Adar1 [112] and 
potential editing effects of Adar1 on the different amino acid codons. The A to G 
Figure 5: Gels for ligation of Adar1 deaminase insert into m2 
plasmid.  
A. Ligation colony PCR with primers RCOL252 and RCOL254.  






mutation caused by Adar1’s deaminase activity is not capable of creating a novel stop 
codon in a sequence (see Table 1), and as such causing a substitution mutation in a 
mutation sensitive part of the protein sequence was the only option. Therefore, the 
search for target options was focused on XAG/XAC/XAA sites in the chromophore 
domain of the eGFP sequence. Tyr-66 (TAC) provided two targeting options both 
leading to a change in fluorescence. An A to G mutation on the coding strand would 
lead to a Tyr to Cys substitution (TAC to TGC), which would inactivate the 
chromophore [113]. Meanwhile, an A to G mutation on the noncoding strand would 
result in a Tyr to His substitution (GTAG → GTGG = TAC → CAC), leading to a strong 
cobalt blue signal but only dim fluorescence [114,115].  
Table 1: The deaminase activity of Adar1 cannot create novel stop codons in a sequence regardless of which 
strand is targeted. 
Second, the positioning of the gRNA relative to the chosen target site was 
considered. Adar1 targets dsDNA [1], and the XTEN-linker should enable the Adar1 
deaminase domain to target an adenine base 7-13 base pairs downstream of the 
A to G mutation on the coding strand 
Creating 
TAG 




Start with TAA, which is already a 
stop codon 
A to G mutation on the noncoding strand,  
causing a T to C mutation on the coding strand 
No Cs in any of the stop codons 





gRNA without interference from dCas9A [11] (see Fig.6), so this was deemed to be 
the optimal setup. gRNAs on both coding (Fig.6A) and non-coding (Fig.6B) strand 
were considered, as either should allow the Adar1 deaminase domain to target Tyr-
66.  
Table 2: eGFP gRNA stats 
eGFP gRNAs CRISPRDirect Feng Zhang lab’s Target 
Finder 
 Sequence including PAM Score Off target sites Mismatches 
between gRNA 
and offtarget site 
20mer 12mer 8mer 
R1 CCCTCGTGACCACCCTGACCTAC 86 119  
(20 in genes) 
2-4 0 6 989 
R2 CCCGTGCCCTGGCCCACCCTCGT 46 360  
(73 in genes) 
2-4 0 74 9041 
 Third, taking all previous criteria into account, suitable gRNAs were assessed 
based on their prediction software scores. gRNAs with higher scores were expected 
to exhibit higher specificity for the selected sequence and thus fewer off-target effects. 
Two suitable gRNAs were designed; R1, CCCTCGTGACCACCCTGACCTAC, and R2, 
CCCGTGCCCTGGCCCACCCTCGT, which were both a compromise between ideal 
software score (see Table 2) and ideal location. The Tyr-66 codon is found at the last 
three bases of R1, while it is located 13 bases downstream of R2.  
A further two gRNAs targeting the eGFP gene were designed by Laurence 
Higgins using slightly different criteria.  
  
7.1.3 eGFP primer design 
The designed primers, GAGGAGCTGTTCACCGGG and CTTGTACAGCTCGTCCATGC, 
were expected to amplify a 702 base pair region encompassing all gRNA target sites. 
The melting temperatures for the primers were 59.73 and 59.00 respectively.  
 
7.1.4 Evaluation of the CJE assay 
The activity of the CJE assay was evaluated using control DNA (see Fig.7). The control 
DNA will create one mismatch upon heteroduplex formation in the A/L sample. Lane 





original uncut band. In lane 3, a further two clear bands appear, indicating digest of 
the heteroduplexes formed. The full size band is in turn slightly faded.  
  
7.1.5 Assessment of gRNAs and wild-type Cas9 plasmids 
293T/GFP-puro cells express eGFP and this fluorescence can be measured by flow 
cytometry. The signal is distinct from non-fluorescent 293A cells (see Fig.8A). 
Transfection with eGFP gRNA without any Cas9 variant did not alter the measured 
fluorescence (see Fig.8B). For all 293T/GFP-puro cell populations transfected with the 
eGFP gRNAs and wild-type Cas9 I saw a consistent reduction of around 50% in GFP 
signal as measured by flow cytometry (see Fig.8D).  
 Transfection with wild-type Cas9 without gRNA did not alter the measured 
eGFP signal. Transfection with wild-type Cas9 and a myc gRNA exhibited a small 
change in eGFP fluorescence for a subset of the cells (see Fig.8C).   
In Figure 9, three different wild-type Cas9 expressing plasmids were tested with 
the eGFP gRNAs; one Church plasmid and two Zhang plasmids. The Church plasmid 
is the expression vector used for the Adar1-Cas9 construct, while the Zhang plasmids 
are used for the BRD8 deletions (see section 6.2.5). All three had a deletion efficiency, 
as measured by loss of GFP signal, around 50% (see Fig.S1).  
Figure 7: CJE assay of control DNA (lane 2 and 3) and DNA from 293T/GFP-puro cells (lane 4 to 7).  
Lane 2 shows the ‘A’ DNA on its own. No mismatches are expected and the CJE does not cut. Lane 3 shows the 
mixed A/L DNA. Besides the full sized band, a further three smaller bands have appeared indicating digest at 
mismatches by the CJE. 
Lanes 4 to 7 show amplified region of DNA from 293T/GFP-puro cells. ‘untransf.’ indicates DNA from 
untransfected cells. The other lanes are named according to the Cas9 variant they were transfected with. They 
were all transfected with four eGFP gRNAs. A clear band is visible 4. Digest at mismatches is apparent in lane 5 





 The wild-type Cas9 mediated deletion in the eGFP gene was also assessed 
using the CJE assay (see Fig.7). As seen on the gel, the DNA from the transfected 
Figure 8: eGFP emission measured by flow cytometry for 293T/GFP-puro cells and 293A cells.  
A. eGFP-expressing 293T/GFP-puro cells and non-fluorescent 293A cells.  
B. Untransfected 293T/GFP-puro cells and 293T/GFP-puro cells transfected with eGFP gRNA but no 
Cas9 variant.  
C. 293T/GFP-puro cells transfected with wild type Cas9 and no gRNA, myc gRNA or eGFP gRNA.  
D. Cells transfected with wtCas9 and eGFP gRNA compared to untransfected cells. The average 
percentage of GFP positive and negative cell populations based on six biological replicates. Error-bars 
showing standard deviation.   
E. 293T/GFP-puro cells transfected with m2Cas9 and no gRNA, myc gRNA or eGFP gRNA. 






cells formed mismatches during heteroduplex formation and was cut by the mismatch 
specific nuclease indicating that the DNA was altered in a subset of the cells. This is 
consistent with the flow cytometry data.  
 
7.1.6 Assessment of the Adar-Cas9 construct 
93T/GFP-puro cells transfected with m2Cas9 and eGFP gRNAs exhibit a small shift 
in measured fluorescence, seen as a small bump in the left side of the fluorescence 
peak (see Fig.8E). 293T/GFP-puro cells 
transfected without gRNA or with myc gRNA do 
not exhibit this change.  
 293T/GFP-puro cells transfected with the 
Adar1-m2CAs9 construct or Adar1 and m2Cas9 
separately are compared to 293T/GFP-puro cells 
transfected with m2Cas9 in Figure 8F. The 
measured fluorescence does not vary 
significantly between the samples. The CJE 
assay did not reveal any mismatches during 
heteroduplex formation (see Fig.7). This 
indicates a lack of mutation in the eGFP gene.  
 
7.2 Assessing the role of BRD8 in antibody diversification and DNA damage 
repair 
7.2.1 The human BRD8 has several potential interaction sites 
Homo sapiens BRD8 has been reported to have at least two isoforms [116,117]; a 
short isoform of 951 amino acid residues containing one bromodomain and a longer 
isoform of 1235 amino acid residues containing two bromodomains. In addition to the 
bromodomains, the predicted domains of both isoforms (visualised in Fig.S2) include 
coiled-coil and low complexity regions. Both of these regions are mediators of protein-
protein interactions [118,119].  
 
Figure 9: Flow cytometry results for wild-type 
Cas9 transfections of 293T/GFP-puro cells.  
One Church plasmid and two Zhang plasmids 
were tested and compared to an 





7.2.2 BRD8 is conserved through vertebrates 
BRD8 is found in several vertebrate species as well as Drosophila melanogaster, but 
for the majority, only a short isoform containing one bromodomain has been annotated 
or predicted including in M. musculus. A BLAT search of the long human BRD8 isoform 
against the mouse genome revealed homologies between the C-terminal end of the 
protein sequence and an open reading frame (4933408B1Rik) immediately 
downstream of the BRD8 gene in the mouse genome (see Fig.10).  
 Multiple alignment of BRD8 sequences from several species show 
conservation of the first bromodomain (see Fig.11). As for the murine BRD8, the long 
isoform containing two bromodomains has not been confirmed in a number of the 
species. Therefore, the second bromodomain does not appear to be conserved. 
However, a multiple alignment of confirmed long isoform BRD8 proteins reveals 
conservation of this as well (see Fig.S5).  
Furthermore, a segment in the N-terminal end of the protein was also found to 
have high conservation (see Fig.11). Subsequent BLAST searches and domain 
prediction for this region came up with no additional information that could elude to the 
function of this region. 
 
Figure 10: BLAT of long human BRD8 isoform against mouse genome Dec. 2011 (GRCm38/mm10).  
A. The whole protein sequence of the long human BRD8 isoform mapped to the mouse genome. 
B. The C-terminal of the long human BRD8 isoform, which is non-overlapping with the short human BRD8 






Figure 11: Multiple alignment of BRD8 from Homo sapiens, Pan 
troglodytes, Mus musculus, Felis catus, Pteropus vampyrus, 
Chelonia mydas, Xenopus (Silurana) tropicalis, Danio rerio, 
Xiphophorus maculatus, Esox lucius, Stegodyphus mimosarum, 








The long human isoform of BRD8 has been reported to share some homology 
with the yeast protein Bdf1 [98]. See supplemental Figure S4 for a pairwise alignment 
between human BRD8 and S. cerevisiae Bdf1. A substantial part of the homology is 
found in the bromodomains. The human proteins, Brd2 and Brd4, which also have two 
bromodomains, also share homology with Bdf1.  
 
7.2.3 Both human and mouse BRD8 interact with subunits of the NuA4 HAT complex 
The STRING networks for human and murine BRD8 show experimental and text 
mining evidence for interactions between BRD8 and several components of the NuA4 
HAT complex (see Fig.12). This is accordance with the literature (see section 5.2.3.3). 
The experimental evidence includes co-immunoprecipitation, affinity capture MS-
assay, affinity chromatography and affinity capture WB-assay[96,97,120–125]. The 
interactions shown have a similar STRING confidence score for binding of 0.900. The 
score is based on experimental data, co-mention in pubmed abstracts and association 
in curated databases; in this case mainly Gene Ontology.  
 
7.2.4 BRD8 is highly expressed in immune cells 
RNA seq data from the BioGPS database reveal that BRD8 is more highly expressed 
in immune cells compared to other tissue types (see Fig.13). Immgen microarray data 
focusing exclusively on murine immune cells further show that the highest expression 
of BRD8 can be found in preB-FrC bone marrow cells and germinal centre cells (see 
Fig.14). VDJ recombination occurs in the former [17], while SHM and CSR take place 
in the latter [126].  
Figure 12: STRING networks for human and murine BRD8.  
The 10 interactors with the highest confidence score are shown. The different coloured lines indicate different 








Figure 14: ImmGen microarray expression data.  
BRD8 (green) and Acta1 (dark grey) expression levels in immune cells based on microarray 
data. The average BRD8 expression level is marked by a black line.  
Figure 13: BioGPS RNA seq data expression data.  
BRD8 expression level in different tissue types calculated from BioGPS RNA seq data. Immune cells, immune 






7.2.5 BRD8 is localised in the nucleus 
Data from Protein Atlas shows that BRD8 is localised in the nucleus and mitochondria 
of U-2OS cells[111]. Endogenous BRD8 was 
visualised using the antibody HPA001841 
(see Fig.15). BRD8 was not found in the 
nucleoli[111].  
 In accordance with this, my own 
immunofluorescence experiments with 
camptothecin treated 293A cells showed an 
accumulation of endogenous BRD8 in the 
nucleus (see Fig.17A-D). However, 
background signal in the cytosol was visible. 
Cells were also stained for the DNA damage 
mark γH2AX. BRD8 was present in the 
nucleus of both damaged and undamaged cells.  
 
7.2.6 Verification of BRD8 deletion in transfected CH12 and 3T3 cells 
Potential BRD8 deletions caused by the 
CRISPR-Cas9 system were verified through 
two approaches; the CJE assay and 
immunofluorescence. For the 3T3 cells, the 
gel of the CJE assay did not reveal any 
additional bands below the original PCR band 
(see Fig.16). The same was seen for DNA 
from CH12 cells (data not shown). Deletions 
in either cell line could not be confirmed 
based on the CJE assay.  
 In 3T3 cells, BRD8 knockout was also 
examined using immunofluorescence. Cells 
were treated with camptothecin to induce 
DNA damage and stained with BRD8 and 
γH2AX antibodies (see Fig.17E-H). As with 
Figure 15: From Protein Atlas. Visualisation of 
BRD8 subcellular localization in U-2OS cells using 
immunofluorescence.  
BRD8 is visualised in green with the antibody 
HPA001841 (A and B), while the microtubules are 
visualised in red (A and B) and the nucleus is 
visualised in blue (B)[111].  
Figure 16: CJE of 3T3 cells transfected with BRD8 
gRNAs*.  
Control DNA ‘A’ and ‘L’ confirm the activity of the 
CJE assay.  
DNA from untransfected 3T3 cells were used for 
control. Two assays were done for each of the two 
gRNAs; one alone and one mixed with control 
DNA at a 1:1 ratio.  





the 293A cells, mainly the nucleus of the cells were stained for BRD8. Both damaged 
and undamaged cells contained BRD8. No nucleus was found without BRD8.  
Figure 17: Immunofluorescence of 293A and 3T3 cells stained with 
BRD8 antibody (red) and γH2AX antibody (green).  







8.1 Developing a modified CRISPR-Cas9 system 
8.1.1 Adar-m2Cas9 expressing plasmid successfully constructed 
PCR and sequencing confirmed the direction and sequence of the Adar1 deaminase 
insert after ligation into the m2Cas plasmid. By using the m2Cas9 plasmid as an 
expression vector, the expressed fusion protein was the Adar1-dCas9 without the 
catalytic activity of the wild-type Cas9. 
 Based on other studies using the Adar1 deaminase domain to target RNA in 
trans, the deaminase activity of Adar1 should be preserved [59]. Thus, the construct 
is expected to be active and capable of deaminating adenosines of suitable substrates.  
 
8.1.2 Four gRNAs targeting the eGFP gene in 293T/GFP-puro cells provided rapid 
estimates of mutations efficiencies of Cas9 expressing vectors  
In collaboration with Laurence Higgins, I established a suitable model for rapid testing 
of various Cas9 variants. The model was based on a 293T/GFP-puro cell line 
continuously expressing the eGFP gene, and four gRNAs targeting this gene. Flow 
cytometry facilitated rapid and easy assessment of the mutation efficiency of Cas9 
variants. Cells transfected with wild-type Cas9 were measured to consist of two 
subpopulations; one negative and one positive for GFP.  
 The CJE assay allowed further assessment of the Cas9 variants at the DNA 
level. The control DNA, with one mismatch in the heteroduplex, validated the activity 
of the CJE. For the cells transfected with wild-type Cas9 at least one additional band 
is apparent in the gel. Four gRNAs were transfected into each cell population. For this 
reason, the heteroduplexes formed before digest with the CJE are expected to contain 
a variation of mismatches. Additional bands could simply be too small or too few to be 
detected by the CJE.  
 Further optimization of the CJE assay will be needed in the future to help detect 
lower deletion efficiency in transfected cell populations. The use of SYBR Gold for 
more sensitive detection of DNA may be enough to allow this. The 293T/GFP-puro 
provides a suitable system for testing this, as deletion percentages can be assessed 






8.1.3 The Adar-m2Cas9 construct did not induce measureable mutations in the eGFP 
gene 
The small shift in fluorescence seen for cells transfected with m2Cas9 can be 
contributed to interference with the transcriptional machinery. This is therefore 
considered as background and used as a control. All measurements from Adar1 
transfected cells should be compared to this control. Potential mutations caused by 
the Adar1-m2Cas9 construct were not detected by flow cytometry or the CJE assay. 
There was no significant difference between the fluorescence measured for cells 
transfected with Adar1-m2Cas9 and cells transfected with m2Cas9 alone.  
It is possible that Adar1-m2Cas9 has deaminated adenosines in a small subset 
of cells making it difficult to measure. Even in the case of high efficiency, it must be 
considered that the Adar1-m2Cas9 may not deaminate the Tyr-66 codon adenosine. 
As previously established, the Adar1-m2Cas9 cannot cause stop mutations. 
Therefore, deamination of adenosines outside the chromophore may not alter the 
eGFP fluorescence. This would not be detectable by our flow cytometry assay. An 
optimisation of the CJE assay may reveal more details in the future. Final confirmation 
of either of these two scenarios would require deep sequencing.  
 
8.1.4 Increased transfection efficiencies could be the key 
The deletion efficiency of eGFP in cells transfected with wild-type Cas9 varied 
depending on the DNA-to-cell ratio. Furthermore, recent transfections using 
LipofectamineTM 3000 reagent (Fisher Scientific) increased deletion efficiency as well 
to more than 90%. This indicates that transfection efficiency is highly important for the 
resultant deletion efficiency. It seems likely that increased transfection efficiencies will 
also influence the efficiency of the Adar1-m2Cas9. Future transfections with this and 
other modified Cas9 systems should be done with LipofectamineTM 3000.  
 
8.1.5 Mismatches could be necessary for Adar1 activity  
Mismatches at or nearby the targeted adenosine increases Adar1 efficiency when 





Adar1 acting on DNA. If Adar1 does indeed target DNA in somatic hypermutation, the 
initial mismatches caused by AID may serve to recruit it. In the attempt to mimic this 
system with Adar1-m2Cas9, perhaps a sequential approach for targeting could be the 
way forward. Whereby the initial mismatches generated by another mutator protein 
may increase the mutation efficiency of Adar1-m2Cas9.   
 
8.1.6 Adar1-dCas9 as a molecular tool 
Optimisation of the Adar-dCas9 system would allow its use in genome engineering. 
There are three different potential uses for this system. 
 First, it could assist in the production and diversification of antibodies ex vivo. 
Currently studies of B cell development and antibody diversification, as well as the 
production of antibodies for research and clinical use, largely rely on whole animal 
models [127–130]. Recent advances have been made by engineering human immune 
organoids capable of driving the germinal centre reactions [131]. However, as of yet 
the processes underlying antibody maturation are not fully understood and the 
processes cannot be emulated in cell culture. The Adar1-dCas9 could be utilised to 
circumvent these poorly understood processes and artificially create somatic 
hypermutation in the variable region of the Ig gene.  
 Second, it would allow for base-specific mutations in situ. The current CRISPR-
Cas9 system can only create DSBs. As such it is limited by the NHEJ repair system 
of the targeted organism. Creating specific point mutations requires a template and 
induction of the homologous repair system of the targeted organism [132]. The Adar1-
dCas9 could potentially simplify this, by targeting specific adenosines guided by the 
gRNA-dCas9 complex.  
 Third, the Adar1-dCas9 could be used to change the epigenetic landscape of 
specific DNA regions. Recently, it was shown that parts of the C. elegans genome is 
methylated on N6-Adenine [133–135]. N6-adenine methylation marks are also found 
on mRNAs in other eukaryotes [136]. A-to-I deamination by Adar1 would result in a 
G:T mismatch. If correctly repaired by MMR, a non-methylated adenine would be 
inserted in the place of the inosine – thus removing the original methylation mark. As 
such, the Adar1-dCas tool may prove useful for elucidating the role of these 






8.2 Assessing the role of BRD8 in antibody diversification and DNA damage 
repair 
8.2.1 BRD8 is highly conserved in vertebrates  
BRD8 is highly conserved in vertebrates, and homologs have been established as 
distantly as U.maydis. The fission yeast protein Bdf1 has been implicated as a possible 
BRD8 homolog. Bdf1 has been implicated in DNA damage repair [137]. However, the 
limited homology between the two can mainly be found in the bromodomains. 
Furthermore, other human bromodomain-containing proteins share a similar 
homology with Bdf1. Therefore, it seems unlikely that Bdf1 is a true homolog of BRD8.  
The high conservation of BRD8 is indeed agreement with an essential role, 
potentially in DNA damage repair and/or transcriptional regulation as implied by its 
interaction partners (see section 8.2.2). A role in antibody diversification is certainly 
possible, but cannot be inferred based on sequence conservation alone.  
 As expected the two bromodomains of BRD8 are highly conserved. A further 
conserved region was found at the N-terminal end of the protein. This region is of great 
interest as it may help uncover specific roles for BRD8. It could be an important 
interaction site or perhaps even a novel domain akin to the bromodomain. Currently, 
no tested domain predictor recognises it. The fission yeast protein Bdf1 does not 
contain a region homologous to this conserved region. The discoveries of true BRD8 
homologs in yeast may help unravel the role of this region.  
 
8.2.2 Multiple interaction partners could exist for BRD8 
The BRD8 sequence contains several predicted low-complexity regions and a coiled-
coil region. These have the potential to mediate interactions with other proteins. There 
is a potential for BRD8 to have several interaction partners. Interaction data 
summarised in a STRING network supports this notion; indicating that BRD8 interacts 
with multiple proteins including other subunits of the NuA4 HAT complex. The literature 
has further implicated BRD8 as a nuclear receptor coactivator [95].  
 Further studies to reveal BRD8 interactions partners would also shed light on 





the most interesting. Kat5 has itself been implicated directly in DNA damage repair 
[85], and indirectly in antibody diversification through the role of the DNA damage 
pathway in CSR (see section 5.2.3). Furthermore, Kat5 is an acetyltransferase. BRD8 
could possibly work downstream of Kat5 mediated acetylation. However, a direct 
interaction between the two could suggest that BRD8 works in conjunction with Kat5. 
Perhaps it anchors it to acetylated regions in order to amplify the acetylation signal. 
The options are many. Unravelling the interaction pattern between the two is certainly 
important for understanding the role of BRD8 in DNA damage repair and antibody 
diversification.  
 
8.2.3 Expression data and shRNA screen results support a role in antibody 
diversification for BRD8 
BRD8 was a hit in a genome-wide shRNA screen for proteins involved in CSR. This 
firmly implicates BRD8 in CSR, and thus antibody diversification. BRD8 expression 
data supports this. BRD8 is highly expressed in immune cells, or immune system 
related cells, compared to other cell types. It is further elevated in two cell types; 
germinal centre cells and pre-B cell bone marrow cells. These are the cell types where 
SHM, CSR, and VDJ recombination occur, respectively. In short, these are the cells 
where antibody diversification takes place. The relatively high expression levels in 
these cell types suggests BRD8 may be involved antibody diversification.  
It seems higher Ig DNA damage correlates with higher BRD8 expression. Many 
proteins are involved in both general DNA damage repair and antibody diversification. 
Indeed, DSB repair is an essential step in CSR. Determining the role of BRD8 in either 
process is likely to reveal its role in the other. It is of course possible that BRD8 is 
involved in several steps of either process. Indeed, the histone mark that recruits Kat5 
to DSBs is found upstream of the AID-initiated DSBs in CSR.  
 
8.2.4 BRD8 localises to the nucleus but does not form foci in response to DNA 
damage 
BRD8 localises to the nucleus (Fig. 15).  Brd8 staining of 3T3 and 293A cells showed 
BRD8 concentrating in the nucleus (Fig. 17). Some background was seen in the 





nonspecific binding. Lowering the antibody concentration or increasing the 
concentration of the mild detergent, TritonX, could eliminate this. Localisation of BRD8 
in the nucleus is in agreement with its possible roles in DNA damage repair and 
antibody diversification.  
 BRD8 was present in both cells with and without γH2AX foci. Also, BRD8 did 
not form foci in response to DNA damage. This is in agreement with the literature. In 
fact, it has been shown, that BRD8 does not re-localise after DNA damage by laser 
microirradiation [93]. It is important to note that this does not refute a role for BRD8 in 
DNA damage repair. Several DNA damage response genes have been shown to have 
essential roles in relaying DNA damage signalling without the necessity to localise to 
DNA damage foci, e.g. CHK1 and CHK2 protein kinases [138]. BRD8, as part of the 
NuA4 HAT complex, is also expected to be involved in transcriptional activation. For 
this reason, it is likely that BRD8 is always needed in the cell at a relatively high level. 
Small changes in protein levels and localisation within the nucleus may not be visible 
by confocal.  
 
8.2.5 CRISPR-Cas9 mediated knockout of BRD8 
The efficiency of the CRISPR-Cas9 system was confirmed in 293T/GFP-puro cells 
with eGFP targeting gRNAs. Unfortunately, BRD8 deletions could not be confirmed in 
3T3 or CH12 cells. Whether this is due to lack of deletion or shortcomings in the assay 
methods is not known. Further optimisation of both the CJE assay and the BRD8 
antibody staining may reveal more.  
Another option must also be considered. It is possible that BRD8 knockout is lethal 
for the cells. Indeed, siRNA knockdown of BRD8 has been shown to affect different 





9 Future directions 
9.1 Developing a modified CRISPR-Cas9 system 
9.1.1 Mismatches and transcription may be required for Adar1 activity 
The Adar1-Cas9 transfections into 293T/GFP-puro will be optimised. The eGFP gene 
provides an excellent target for this with easily measurable results. Optimisation of the 
CJE assay alongside should increase ease the analysis of the Adar1-Cas9 effect on 
the eGFP locus.  
Current work includes a sequential approach with another Cas9-fusion protein 
capable of creating mismatches. Preliminary results from these double-transfections 
are positive. The eGFP signal is shifting more than for either Cas9-fusion alone.  
Induction of transcription in the targeted region also has an effect. The role of 
transcription is unknown. The Adar1-m2Cas9 does not contain the Z-DNA binding 
domain, so the induction of Z-DNA formation should not play a role. Whether Adar1 is 
exerting its deamination on the transcribed RNA or perhaps the ssDNA is not known. 
Further studies are needed and deep sequencing of the targeted region should reveal 
more.  
Changes to the Adar1-m2Cas9 construct may also be necessary for optimal 
efficiency. Fusion of dCas9 to the N-terminus of Adar1 or changes to the linker 
between the two should be considered.  
 
9.1.2 Elucidate the role of Adar1 in antibody diversification in vivo 
The imitation of SHM through the CRISPR-Cas9 system is interesting on several 
levels. When optimised the construct has several potential uses, and it may assist in 
unravelling the role of Adar1 in SHM in vivo. However, for a full understanding of this 
role, in vivo assays in suitable models are necessary. Knockout or inhibition of Adar1 
could prove useful in determining the effect of Adar1. Separating its canonical dsRNA 
activity from its potential DNA activity may prove difficult. Here, the synthetic system 
may be more suitable. A decrease in GFP measured by GFP without the 
corresponding mutations being visible in an optimised CJE assay, would indicate 





 In this thesis, I have attempted to utilise the deamination capability of Adar1 to 
imitate SHM ex vivo. That is not to say that it is not involved in both SHM and CSR in 
vivo. Indeed, the Z-DNA binding domain of Adar1 has been shown to bind G-
quadruplexes [139]. This interaction mediates the recruitment of Adar1 to the myc 
promotor [139]. Recently, G-quadruplexes were shown to mediate the recruitment of 
AID to the switch regions [61]. In the absence of switch region G-quadruplexes CSR 
was impaired [61]. Adar1 could potentially be recruited to switch regions in a similar 
way.  
 
9.2 Assessing the role of BRD8 in antibody diversification and DNA damage 
repair 
9.2.1 Identify potential BRD8 homologs in yeast 
Although BRD8 shares homology with yeast Bdf1 [98], the evolutionary relationship 
between the two is still questionable. Focusing on the N-terminal conserved region, 
further searches will be carried out in an attempt to find true yeast homologs. This 
region is of particular interest in terms of BRD8 functions, and homologs in yeast may 
help uncover this.  
 
9.2.2 Verify BRD8 deletions in mouse cells 
Mouse cells are a suitable model for antibody diversification and DNA damage repair 
because of their close relation with human cells. However, it is important to take into 
consideration, that only the short isoform of BRD8, containing a single bromodomain, 
has been annotated in mouse. Therefore, the murine BRD8 will be characterized 
further. The possibly incorrectly annotated region downstream of (see section 7.2.2), 
and available RNA sequencing data from mouse cells will aid this characterization.  
The BRD8 deletions in 3T3 and CH12 cells will be verified. Optimisation of the 
CJE assay for better visualisation of fainter bands could potentially reveal deletions 
that have not been verified as of yet. Further optimisation of the IF assay could do the 
same. The presence or absence of the BRD8 protein will also be assayed using 






9.2.3 Isolate BRD8 deletion clones for 3T3 and CH12 cells 
Upon verification of deletion the cells will be diluted. Single clones will be picked and 
BRD8 deletion verified with CJE and IF. Sequencing of these clones will then confirm 
the exact nature of the knockout.  
 If BRD8 deletion is lethal for the cells, other measures need to be taken. A 
specific inhibitor for BRD8 would be of great use. However, due to the homology 
between bromodomain-containing proteins, development of such an inhibitor is 
difficult. Knock-out of BRD8 followed by transfection with an inducible BRD8-
expression system is a more viable option. This would allow for controlled inhibition of 
BRD8 expression. Alternatively, siRNA knockdown may be an option. Up to 95% 
knockdown has been achieved [94].  
9.2.4 Assess DNA damage response in ∆BRD8 fibroblast cell lines 
DNA damage will be induced through camptothecin and irradiation and the DNA 
damage response will be assessed for wild-type cells and ∆BRD8 cells. The 
accumulation of γH2AX at DSBs will be assayed using flow cytometry and IF. In this 
way, I can determine if BRD8 functions upstream or downstream of the γH2AX mark. 
Based on its interaction with Kat5, it is expected to function alongside Kat5 upstream 
of γH2AX.  
 
9.2.5 Assess antibody diversification in ∆BRD8 CH12 cells 
CH12 cells are capable of switching from IgM to IgA, so they provide an excellent 
model for studying CSR. The proportion of IgA switched cells within a population will 
be assayed using fluorescent antibodies and flow cytometry. Comparison of wild-type 
cells and ∆BRD8 cells will help unravel the role of BRD8 in CSR. Combination assays 
with Kat5 inhibition in ∆BRD8 cells may reveal more; both about the BRD8-Kat5 
interaction and their roles in antibody diversification.  
 
9.2.6 Deletion of BRD8 in human cells  
While murine cells are an excellent model for DNA damage repair and antibody 
diversification, human cells may reveal additional information. gRNAs have been 





knock-out the BRD8 gene in human 293A fibroblast cells. These can be used for 
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CJE   Celery Juice Extract 
crRNA  CRISPR RNA 
CRISPR   Clustered Regularly Interspaced Short Palindromic Repeats  
CSR   Class-Switch Recombination 
DSB   Double-strand break  
gRNA   guideRNA 
HR   Homologous recombination 
NHEJ   Non-homologous end joining  
PEI   Polyethylenimine 
SHM   Somatic Hypermutation 
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12 Supplemental figures 
 




Figure S 1: FACS results for wildtype Cas9 transfections of 293T/GFP-puro cells.  













Figure S 2: Human long isoform BRD8 domain prediction by SMART. 
Green = coiled-coil. Pink = low-complexity region.  
Figure S 3: S-cerevisiae Bdf1 domain prediction by SMART. 
Green = coiled-coil. Pink = low-complexity region.  






Figure S 5: Multiple alignment of the long isoform BRD8 from Homo 
sapiens, Pan troglodytes, Cricetulus griseus, Sorex araneus, Condylura 
cristata, Felis catus, Ovis aries, Equus przewalskii, Pteropus vampyrus, 
Odobenus rosmarus divergens, Tursiops truncates, Alligator sinensis 
and Chelonia mydas.  
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